Administration makes it easier for drugmakers to profit from publicly funded coronavirus drugs, critics say

WASHINGTON - The Trump administration is weakening taxpayer safeguards in its agreements with companies working on novel-coronavirus drugs, which could prevent regulators from curbing prices for future vaccines and treatment, a consumer group said Wednesday.

In its race to control covid-19, the disease the virus causes, the federal government is spending billions in agreements with pharmaceutical companies to subsidize development of medicines...